Clinical Trial

Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 6, 2025 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
To demonstrate the efficacy of Clascoterone cream 1% in reducing the size of sebaceous glands in study participants with acneiform rosacea.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-23.
Trial Details
NCT Number NCT06952517
Lead Sponsor Narrows Institute for Biomedical Research
Collaborators: Sun Pharmaceutical Industries Limited
Conditions Papular-pustular Rosacea, Papulopustular Rosacea (PPR), Papulopustular Rosacea
Enrollment 20 participants
Start Date 2025-03-14
Primary Completion 2025-09-01 (estimated)
Study Completion 2025-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-06